SMITHKLINE OFFERS NEW DRUG FOR OVARIAN CANCER
By Adnews Staff
SmithKline Beecham of Toronto has released a new drug for the treatment of patients with ovarian cancer. Called Hycamtin, the drug is for patients who have failed initial or subsequent chemotherapy. It kills cancer cells by inhibiting an enzyme that is essential for the growth of tumors. The drug is being promoted using medical journal ads created by Anderson Advertising of Toronto. PR is being done by Juniper Communications of Oakville, Ont. SmithKline Beecham is also involved in a number of clinical trials evaluating how this drug may be useful in other tumor types including small-cell lung, non small-cell lung, leukemia and lymphoma.
« Back Next »
Comments
blog comments powered by Disqus